Cost-effectiveness study of pediatric atopic dermatitis in Asia: atopiclair vs. regular emollient (AD-ATOP)

Insights

Atopiclair, a non-steroidal cream, is a cost-effective treatment for childhood atopic dermatitis (AD) compared to regular emollients. It offers significant annual cost savings across high, middle, and low-income Asia-Pacific countries.

Area of Science:

  • Dermatology
  • Health Economics
  • Pediatrics

Background:

  • Atopic dermatitis (AD) is a common childhood condition impacting quality of life.
  • Current AD management relies on proactive moisturizing treatments.

Purpose of the Study:

  • To evaluate the cost-effectiveness of Atopiclair versus regular emollient for pediatric mild-to-moderate AD.
  • Study focused on 12 Asia-Pacific countries.

Main Methods:

  • A Markov decision model was utilized for cost-effectiveness analysis.
  • Data sourced from literature review, expert opinion, fee schedules, and a 2012 survey.
  • Analysis adopted a societal perspective.

Main Results:

  • Atopiclair demonstrated cost-effectiveness against regular emollient.
  • Annual cost savings per patient were USD786 (high-income), USD499 (middle-income), and USD289 (low-income).
  • Sensitivity analyses confirmed Atopiclair's cost-effectiveness.

Conclusions:

  • Modeling indicates Atopiclair is a cost-effective option for managing pediatric mild-to-moderate AD.
  • This finding applies to the studied Asia-Pacific nations.
Abstract